《2023 CSCO非小细胞肺癌诊疗指南》罕见靶点诊疗更新

Diagnostic and Therapeutic Strategy Updates of Rare Oncogenic Mutations in Chinese Society of Clinical Oncology Guidelines on Diagnosis and Treatment of Non-small Cell Lung Cancer (2023 Edition)

摘要: 2023年4月中国临床肿瘤学会(CSCO)发布了新版非小细胞肺癌(NSCLC)诊疗指南, 其中针对ROS1融合、BRAF V600E突变、NTRK融合、MET 14外显子跳跃突变、RET融合、EGFR 20号外显子插入突变等罕见靶点的诊疗策略均有更新。本文将从诊断、一线及后线治疗对新版指南中上述罕见靶点诊疗的更新要点作一介绍, 并作详细解读。

Abstract: The Chinese Society of Clinical Oncology (CSCO) issued the new version of the guidelines on diagnosis and treatment of NSCLC in April 2023.The new version updated the diagnostic and therapeutic strategy of rare oncogenic mutations, including ROS1 fusion, BRAF V600E mutation, NTRK fusion, MET exon 14 skipping mutation, RET fusion, and EGFR exon 20 insertion mutation, in NSCLC.This review will interpret the most important updates in the guidelines 2023 regarding the diagnosis as well as first-line and post-line therapies of these rare oncogenic mutations.